Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC

SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) claims almost 80% of the total lung cancer cases, with the late-stage disease having an estimated median survival time of up to five years. Patients with NSCLC benefit from traditional maximum tolerated dose (MTD) chemotherapy alone or combined with...

Descripción completa

Detalles Bibliográficos
Autores principales: Skavatsou, Eleni, Semitekolou, Maria, Morianos, Ioannis, Karampelas, Theodoros, Lougiakis, Nikolaos, Xanthou, Georgina, Tamvakopoulos, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071233/
https://www.ncbi.nlm.nih.gov/pubmed/33920884
http://dx.doi.org/10.3390/cancers13081901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071233/
https://www.ncbi.nlm.nih.gov/pubmed/33920884
http://dx.doi.org/10.3390/cancers13081901

Ejemplares similares